Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Broncus Holding's share price for the quarter that ended in Jun. 2024 was HK$0.6. Broncus Holding's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 527.20 Mil. Therefore, Broncus Holding's market cap for the quarter that ended in Jun. 2024 was HK$316.32 Mil.
Broncus Holding's quarterly market cap
declined
from Jun. 2023 (HK$601.00 Mil) to Dec. 2023 (HK$386.05 Mil) and
declined
from Dec. 2023 (HK$386.05 Mil) to Jun. 2024 (HK$316.32 Mil).
Broncus Holding's annual market cap
declined
from Dec. 2021 (HK$4,336.20 Mil) to Dec. 2022 (HK$1,118.20 Mil) and
declined
from Dec. 2022 (HK$1,118.20 Mil) to Dec. 2023 (HK$386.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Broncus Holding's Enterprise Value for Today is HK$-244.77 Mil.
Broncus Holding Market Cap Historical Data
The historical data trend for Broncus Holding's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Broncus Holding's Market Cap
For the Medical Devices subindustry, Broncus Holding's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's Market Cap distribution charts can be found below:
* The bar in red indicates where Broncus Holding's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Broncus Holding's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (HKSE:02216) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Broncus Holding Market Cap Related Terms
Thank you for viewing the detailed overview of Broncus Holding's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02216 has been successfully added to your 